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Abstract
The currently used immunosuppressive drugs have a narrow therapeutic index which required to individualize 
the dose regimen for different recipients. Pharmacogenetic is the use of genetic screening to prevent metabolic 
responses to different immunosuppressive drugs. Since the oxidative enzymes cytochrome P450 CYP3A and the 
drug efflux pump P-glycoprotein (P-gp) play a pivotal role in immunosuppressive drugs metabolism, pharmacogenetic 
studies have been mainly focused on these two enzymes. This would provide an important aid toward drug regimen 
individualization during the post-transplant therapy and has potential to improve graft outcome.
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Introduction
Organ transplantation is becoming the optimal therapy strategy 
for end stage renal, liver heart and lung diseases. The introduction of 
better and more specific immunosuppressive drugs have enable organ 
replacement to obtain its current place. In fact, a gradual improvement 
in short-term graft survival has occurred over the last 10 years and 
extensive use of the calcineurine inhibitors (CI) tacrolimus and 
cyclosporine, have played a not negligible role [1]. However, there has 
been minimal improvement in long term graft survival over the same 
period partly due to drug side effects [2,3]. It is well recognized that 
response to CI has significant inter and intra individual variation in 
transplant patients. Both over and under-dosage of CI influence the life 
span of the graft and of the recipient [4,5]. Several factors such as organ 
function, drug interaction and the nature of the disease may influence 
the effects of CI. Recently, the role of genetic factors has been also 
pointed out since genetic polymorphisms are implicated in the inter-
individual variability of the pharmacokinetic and pharmacodynamic 
characteristics of many drugs. Pharmacogenetic is the study of genetic 
variations that give rise to different drug responses and theoretically 
represents a very promising tool. A genetic screening prior to 
transplantation should allow to forecast the individual response to a 
given immunosuppressive drug therefore to tailor immunosuppressive 
regimen in order to optimized short and long term outcomes.  
Metabolic Pathways as Possible Targets for a 
Pharmacogenetic Strategy
The genes that are primarily involved in metabolizing 
immunosuppressant are those encoding cytochrome P450 (CYP) 
3A family enzymes and multidrug resistance P-glycoprotein 1 (the 
ABCB1gene). As many drugs undergo substantial intestinal and liver 
metabolism after absorption from the gut lumen, it is believed that 
CYP3A and P-glycoproteinare are lagely responsible for the poor oral 
bioavailability of calcineurin inhibitors [6]. The CYP3A subfamily 
is a cluster consisting of four isoenzymes. CYP3A4 and CYP3A5 
are the main genes involved in the metabolism of cyclosporine and 
tacrolimus [7]. CYP3A5 is expressed more variably and at a relatively 
higher level in the proximal renal tubules [8]. CYP3A5*1 encodes 
an active protein and is responsible for the increased metabolism of 
many drugs including tacrolimus but not cyclosporine [6]. During the 
transcription phase, the CYP3A5*3 (6986 A>G) allele introduces an 
alternative splicing site leading to protein truncation, thus resulting 
in the absence of full-length protein expression [9,10]. CYP3A4 is 
abundantly and constitutively expressed in hepatic and intestinal 
epithelia, so the reported increase in transcriptional activity shown 
by the CYP3A4*1B allele in vitro would theoretically also reflect 
significant enzymatic activity in vivo [11]. P-gp, which is encoded by 
the ABCB1 gene, is a large ATP-dependent transmembrane protein 
involved in the extracellular extrusion of many xenobiotics and 
drugs including calcineurin inhibitors (CNIs) [12]. Cyclosporine 
is a typical ABCB1 substrate and intestinal P-gp may be responsible 
for the reduced intestinal absorption of cyclosporine [13]. More than 
700 variations in the nucleotide sequences have been described and 
although nothing is known about the clinical impact of most of the 
sequence variations on P-gp function, some seem to be functionally 
relevant and substantially influence the pharmacokinetics of substrate 
drugs. The most extensively investigated SNPs of ABCB1 are 3435C > 
T (rs1045642) in exon 26, 1236C > T (rs128503) in exon 12 and 2677G 
> T/A (rs 2032582) in exon 21 [14]. The 3435C > T polymorphism 
is a silent polymorphism that may be in linkage disequilibrium with 
other functional polymorphisms in the ABCB1 gene, including 2677G 
> T/A. The 3435C > T polymorphism may also reduce ABCB1 mRNA 
stability in the liver and it could change protein folding and activity 
[15]. Another interesting SNP is IVS21+49 T > C (rs2032583) in intron 
21 of ABCB1, which is involved in the pharmacokinetics of many drugs 
including antidepressants and methadone [16].
CYP3A5 and ABCB1 Genotypes and Tacrolimus
The expression of CYP3A5 is associated with reduced tacrolimus 
exposure following oral administration in both pediatric and adult 
population [17,18]. CYP3A5 expressors exhibit a significant delay in 
achieving target blood concentration [19]. Therefore, an increased 
incidence of acute rejection episodes in the early post-transplant period 
has been reported [20]. Recently, the first study to show the prospective 
adaptation of tacrolimus daily dose based on CYP3A5 patient’s 
genotype, confirmed that pre-transplant genetic screening increased 
significantly the proportion of patients reaching the therapeutic target 
range. In fact, in this multi-center randomized controlled trial, patients 
receiving tacrolimus daily dose according to their CYP3A5 genotype, 
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achieved the target concentration more rapidly with lesser dose 
modification and in an higher percentage ( >75%) when compared 
to those in whom tacrolimus was managed with a concentration-
control strategy [21]. ABCB1 polymorphisms do not seem to influence 
tacrolimus pharmacokinetic and research into this association has 
yielded mixed results [22,23]. Nevertheless, in our series we observed 
a significant reduction in tacrolimus concentration and dose-adjusted 
tacrolimus concentrations in the early post-transplant period for 
the TT polymorphism of C1236T; this suggests that there is higher 
metabolism of the drug in subjects with this genotype [24]. This could 
be substantiated by the fact that 1236 and 3435 polymorphisms of 
ABCB1 influence the shaping and stability of mRNA and, consequently, 
gene expression [25]. Interestingly, a recent study on pediatric liver 
transplantation demonstrated a significant association between ABCB1 
polymorphisms and tacrolimus-related nephrotoxicity [26]. This 
suggests that ABCB1 polymorphisms in the gastrointestinal tract do 
have an influence on tacrolimus dose requirement and exposure. 
CYP3A5 and ABCB1 Genotypes and Cyclosporine
There are a number of conflicting reports regarding the CYP3A 
genotype influence on cyclosporine pharmacokinetic [27,28]. 
Therefore, a clear role of this polymorphism on cyclosporine 
metabolism has not been demonstrated. However, it is necessary to 
bear in mind that the drug is simultaneously both a substrate and 
an inhibitor of ABCB1 [29] which is why the influence of ABCB1 
polymorphisms is rather controversial. In our series, we found that 
ABCB1 polymorphisms affected cyclosporine pharmacokinetics in the 
immediate post-transplant period rather later [24]. The time-related 
effect of ABCB1 polymorphisms may be explained by the fact that the 
drug’s potent inhibitory effect on P-gp function requires an adequate 
pharmacological load before it is fully expressed [30]. Another possible 
explanation should be related to the age of the recipients. Recently, 
Fanta and colleagues suggested that age-related polymorphisms of 
ABCB1 could explain the different oral bioavailability of cyclosporine 
among different age groups [31]. 
The Effect of Donor Genetic Polymorphisms on the 
Transplant Outcome
Among the genetic variables that might affect immunosuppressive 
drug metabolism, consideration should be given to the possible role 
of donor genotype. In fact, grafts from donors may carry different 
genotypes from CYP3A5 and ABCB1. However very few data are 
available on whether and how much the donor graft genetic background 
influence absorption and metabolism of immunosuppressive drugs. 
This would mainly apply to liver transplantation where particular 
receptors in the donor’s graft have been reported to substantially affect 
tacrolimus metabolism [32,33]. In the kidney transplant setting there 
have been relatively few studies looking at the role of polymorphisms 
in graft donors and their conclusions remains unclear. Woillard 
et al. [34] reported that the presence of ABCB1 polymorphisms 
in donors influenced long-term graft outcome of renal transplant 
patients. Nevertheless, Hauser et al. [35] reported that in adult renal 
transplant recipients the incidence of cyclosporine nephrotoxicity was 
significantly higher when the donor rather than the recipient, had the 
ABCB1 3435TT genotype. Obviously, intra-graft ABCB1 expression is 
related to donor’s genotype and possibly responsible for cyclosporine 
accumulation in renal tubular cells. Further studies are required to 
evaluate the role of donor polymorphisms although it is likely that 
in pediatric and adult renal transplantation the role of recipient 
polymorphisms will be more important.
Conclusions
In organ transplantation the poor bioavailability and the large 
intra and inter-individual variability in the administration of 
immunosuppressive drugs limit the postoperative drug therapy, 
which may subsequently affect the function and lifespan of grafts. The 
individualization of the therapeutic regimens in different patients is 
mandatory in order to balance clinical efficacy and toxicity. CYP3A and 
P-gp are the two key enzymes which greatly influence the absorption, 
disposition, metabolism and clearance of immunosuppressive drugs. 
Many genetic factors have been identified to affect the expression of 
CYP3A and P-gp and up to day there is a large evidence base relating to 
genetic influences on the pharmacology of calcineurine inhibitors. The 
pre-transplant screening of the most relevant polymorphisms should 
therefore be considered in order to tailor immunosuppressive therapy 
to an individual patient’s metabolism.
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